02:03 PM EST, 03/06/2024 (MT Newswires) -- Creative Medical Technology Holdings ( CELZ ) shares were up 23% in recent trading on Wednesday after the company said it received orphan drug designation from the US Food and Drug Administration for its CELZ-101 candidate.

Creative Medical ( CELZ ) is developing CELZ-101, or ImmCelz, to prevent allograft rejection in patients undergoing pancreatic islet cell transplantation, according to the company.

Price: 4.73, Change: +0.66, Percent Change: +16.29